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Age modulates the injury-induced metallomic
profile in the brain†
Stuart D. Portbury,a Dominic J. Hare,ab Charlotte J. Sgambelloni,a David P. Bishop,b
David I. Finkelstein,a Philip A. Dobleb and Paul A. Adlard*a
The biological transition metals iron (Fe), copper (Cu) and zinc (Zn) are thought to contribute to the
neuronal pathologies that occur following traumatic brain injury (TBI), and indeed our previously
published work in young (3 month-old) mice clearly demonstrates a significant spatiotemporal
modulation of metals following TBI. Of note, however, is the literature observation that there is both an
apparent detrimental effect of aging on TBI outcomes and an alteration in metals and their various
transporters with normal advancing age. Therefore, to determine whether there was an interaction
between aging, metals and TBI, we have utilised laser ablation-inductively coupled plasma-mass
spectrometry to examine the spatial and temporal distribution of Fe, Zn and Cu following an acute
controlled cortical impact brain injury in aged (24 months) rodents. The relative abundance of metals in
corresponding regions within the ipsilateral and contralateral hemispheres as well as the hippocampus
was assessed. Substantial region and time point specific alterations in Fe, Zn and Cu were identified
immediately and up to 28 days post-TBI. The data from this follow-up study has also been compared to
our previous data from young animals, and aged mice exhibit an appreciably enhanced and persistent
elevation of all metals in every region surveyed, with individual metal disparities at various time points
observed post-injury. This may potentially contribute to the acceleration in the onset of cognitive
decline and neurological disease that has been observed in the aged population following head trauma.
Significance to metallomics
Metals play critical roles in brain health. The spatial changes we have observed in the levels of iron, zinc and copper in the aged brain, both in naı̈ve and brain
injured animals, highlight the potential interaction of these metals in both age- and injury-related functional deficits. This suggests the use of metal-targeted
therapeutics could be used to improve outcomes post-injury.
Introduction
Traumatic brain injury (TBI) is a rapidly growing international
health concern that is complicated by the diversity in severity,
injury type and epidemiological patterns of TBI incidence.1,2
Along with suicide, it is a major cause of death and disability in
young people,1,3 with injury modalities including falls, assaults,
motor vehicle accidents and blunt force trauma.4 In its ‘World
report on traffic injury prevention’, the World Health Organization
(WHO) estimates that by 2020, road traffic accidents would be
within the top three leading causes of global burden of disease,
surpassing even HIV and tuberculosis.5 Although the form of TBI
varies on a near case-by-case basis, there is a shared stereotypical
response to the injury that includes, amongst other features,
inflammation,6 release of serum and cerebrospinal fluid-based
markers,7 and axonal injury.8 The age at which injury is sus-
tained is an additional factor that indirectly contributes to
morbidity and mortality and is now recognised as a risk factor
for dementia.9 A recent comprehensive study by Gardner et al.
assessed 164 611 patients with trauma, aged Z55 years at the
time of injury, and clearly demonstrated the influence of age on
dementia risk following TBI.10 Moreover, even a single mild TBI
conferred an elevated dementia risk in patients aged Z65 at
the time of injury. This study is supportive of earlier reports
indicating a significant association between age and TBI leading
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to increased mortality, as well as unfavourable clinical outcomes
in elderly patients with either mild11 or severe TBI;12,13 including
the potential for TBI to proceed or initiate the onset of debilitating
and fatal disorders such as Alzheimer’s disease (AD),14 amyotrophic
lateral sclerosis (ALS),15 and Parkinson’s disease (PD).16,17 Con-
sistent with this, widespread tau and amyloid-beta pathology, the
characteristic hallmarks of AD, have been shown to persist for
many years after a single TBI18 and chronic inflammation and
ongoing white matter degeneration have also been observed as
an enduring legacy of a single TBI many years after the initial
insult.19 Similarly, in TBI experiments with mice, aged animals
have a demonstrated inferior performance in behavioural tests,
exhibit exacerbated chronic inflammation with prolonged activa-
tion of both astrocytes and microglia, and display pathological
iron deposits co-localised with T2 hypointensities via magnetic
resonance imaging when compared to younger adult mice.20–22
The latter relates to a common biochemical feature of TBI and
age associated dementias such as AD, where there is a disordered
regulation of the biologically critical transition metals iron (Fe),
copper (Cu) and zinc (Zn).23 These observations have led to the
metal dyshomeostasis theory, which implicates metals in the
cellular cascades that contribute to AD, PD, ALS and other
conditions.26,27 Whether metals are critical in the onset and/or
progression of disease, or even normal aging, is yet to be
definitively established, although it is likely that an age-related
modulation of metal ions and their transporters are a contributing
factor.
For instance, Fe storage increases with age in the human
brain in the cortex, hippocampus and basal ganglia, and the
main cell types shown to accumulate Fe are microglia and
astrocytes.28 The labile iron pool can increase to potentially
harmful levels whereby elevated and unregulated reactive oxygen
species (ROS) can lead to oxidative damage and cell death.
Accumulation of Fe in specific brain regions occurs in many
neurodegenerative disorders of ageing and is usually associated
with oxidative stress and subsequent cellular injury and death.
Similarly, a disruption in Zn levels can cause profound
neuronal damage and disruption of synaptic activity. Zn is
readily dissociated from its binding proteins in cells under-
going changes in redox state due to unregulated production
of reactive oxygen species,29 and the liberated Zn ions have
been established as a potent inducer of neuronal injury.30 The
increased and unregulated production of ROS is a major contri-
butor to the pathological changes associated with normal
ageing and particularly age-related disorders of the brain.
Conversely, however, adequate concentrations of Zn are
required for normal neurotransmission, and synaptic vesicular
Zn is required for normal memory function,31 and the Zn
transporter responsible for loading presynaptic vesicles with
Zn (ZnT3) has been shown to decrease with age in both rodents
and humans.31
Finally, Cu is an essential element in the central nervous
system (CNS). However, its propensity to form ROS renders it
toxic in situations where an increase in labile species is
observed.32–35 Increased Cu levels have been observed in rodent
models of human aging.34,36 However, diminished Cu levels are
reported in the frontal, occipital and parietal lobes37 amygdala
and hippocampus in AD.38 Thus, the age and disease-dependent
modulation of metals provides a complex landscape on which TBI
can occur, and which TBI can influence.
We recently reported a time-course analysis of changes
in cerebral metals post-TBI in young adult mice utilising
laser ablation-inductively coupled plasma-mass spectrometry
(LA-ICP-MS). Our results demonstrated a potentially injurious
sustained elevation of non-heme associated Fe in the ipsilateral
cortex.25 In this study we sought to provide clarity around
the age-related changes in metal levels that occurs in the
CNS, under both baseline conditions and following a TBI.
These studies may provide insight into mechanisms underlying




All procedures were carried out in accordance with protocols
approved by the Howard Florey Animal Ethics Committee and
were conducted in accordance with the Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes
as described by the National Health and Medical Research
Council of Australia.
Controlled cortical impact model
Controlled cortical impact (CCI) was carried out using a Hatteras
PCI 3000 precision cortical impactor (Hatteras Instruments,
Cary, NC). 24 month-old male C57Bl6 mice were anesthetised
via intraperitoneal injection of 100 mg kg1 ketamine and
10 mg kg1 xylazine. Anesthesia was monitored via respiration
and pedal retraction reflexes. Upon adequate anesthesia the
surgical site was clipped and shaved and cleansed with 70%
ethanol. A 10 mm mid-line incision was made over the skull,
and the skin and fascia were reflected to make a 4 mm
craniotomy on the central aspect of the right parietal bone
using a motorised drill (AP-2.25 mm, lateral 2.5). Excised bone
was placed in sterile PBS until resituating post-injury. The
animal was then positioned in a stereotaxic frame. The 3 mm
impact tip of the CCI was lowered to the surface of the exposed
dura, signified by an audible contact alarm, and the injury subse-
quently delivered (3 m s1 velocity with a 1.5 mm penetration
depth). The excised bone was then replaced and glued in position
with super glue, the skin similarly glued together and the animal
then placed in a 37 1C heated cage until completely ambulatory.
Animals did not receive any analgesia post-surgery.
Animals were euthanised at 24 h (n = 4), 72 h (n = 3), 7 day
(n = 3), 14 day (n = 4) and 28 day-post surgeries (n = 4), and
animals without injury (n = 3) were euthanised on day 28 only.
For the 3 month-old ESI,† animals were euthanised at 24 h
(n = 5), 72 h (n = 4), 7 day (n = 4), 14 day (n = 5) and 28 days’ post
surgeries (n = 4). Animals were anesthetised with Nembutal,
before a 50 mL pericardial perfusion with ice-cold 4% para-
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incubated in PFA (4% in PBS at 4 1C), followed by immersion in
a cryoprotective solution for 7 days (30% sucrose in PBS, 4 1C).
Sections were subsequently cryostat sectioned at 30 mm inter-
vals at 20 1C and mounted on standard microscope slides.
Sections were stored at80 1C prior to analysis, when they were
air-dried at room temperature.
LA-ICP-MS imaging
Analysis was performed using a New Wave Research UP213
laser ablation system with a two-volume large format cell
(ablation area 15  15 cm). This system was hyphenated to
an Agilent Technologies 7500ce ICP-MS fitted with ‘cs’ lenses
for enhanced sensitivity. Quantitative data was obtained by
representative ablation of matrix-matched tissue standards
produced according to the protocol previously reported.39
Hydrogen was used as a reaction gas at a flow rate of 3 mL
min1 to remove potential interferences arising from trace
oxygen impurities in the argon gas used, particularly 40Ar16O+
on 56Fe+.40 The specificity of hydrogen for reducing interference
on Fe was the main determinant of its selection; non-specific
collision gases such as helium reduce signal to noise ratios and
do not attenuate interferences effectively in LA-ICP-MS.41 We
have recently shown that matrix-based interference formation
at biologically-relevant concentrations are negligible using these
experimental conditions.42 Measured masses included m/z = 56
for Fe, 62 for Cu and 66 for Zn with an integration time of 0.08
seconds per mass. Limits of detection (LOD) and quantification
(LOQ) were 0.55 mg g1 and 1.58 mg g1 for Fe; 1.20 mg g1 and
1.89 mg g1 for Cu; and 0.39 mg g1 and 1.08 mg g1 for Zn.
Image construction and region of interest selection
Horizontal lines of ablation were drawn across both ipsilateral
and contralateral upper quadrants of the selected section. Lines
of ablation were spaced apart the same distance as the laser
beam diameter. A beam diameter of 30 mm was used, traversing
the section at a speed of 120 mm s1, laser fluence of 0.3 J cm2
and repetition rate of 20 Hz. The ICP-MS was configured to
collect 4 data points per second40 thus the resultant images had
pixel dimensions was equivalent to 30  30 mm2 (total pixel
area = 900 mm2). Images were produced by reducing multiple
ablation lines into ASCII data files via a Python script for
importing into ENVI 6.0 (Exelis Visual Information Solutions,
Boulder, CO, USA), from which regions of interest (ROIs) were
extracted and statistically analysed. Each ROI represents a
rectangular quadrant that radiates outwards from the impact
site towards the centre of the brain, or the equivalent region on
the contralateral side of the brain (Fig. 1).25 One brain slice per
animal underwent ablation and subsequent analysis. Additionally,
the hippocampus was manually extracted as an individual ROI
using the Zn map43 for analysis without adjacent tissue of any
ROI region (Fig. 1). ROIs had average areas of: ROI1 (cortex)
835.1  326 mm2; ROI2 (cortex, hippocampus and white
matter) = 3129  486 mm2 (minus the area of ROI1); ROI3
(thalamus and cortex) = 6116  885 mm2 (minus ROI 1 and 2).
The mean area of the entire dorsal hemisphere was 10.08 1.46 cm2.
Total areas of extracted ROIs were equivalent between ipsilateral
and contralateral sides.
Statistical analysis
Statistical analysis was carried out in Prism 6.0 h (Graph-Pad,
La Jolla, CA, USA). Analysis was carried out using either a
two-tailed t test or a two-way ANOVA as appropriate, with
significance recognised as p o 0.05.
Results
Representative examples of time course LA-ICPMS images of
the left and right hemispheres are shown in Fig. 2.
Iron levels are significantly altered after brain injury
Analysis of spatial distribution and concentration of Fe across
the time course following TBI revealed a sustained and con-
tinually increasing elevation in each region examined (Fig. 3).
A comparison of ipsilateral to contralateral hemispheres
revealed that, after TBI, the Fe levels were significantly increased
within the immediate vicinity of the impact site (ROI1 p o 0.0001;
Fig. 3a) and in the two additional ROIs extending radially from the
lesion site (ROI2 p o 0.0001; ROI3 p o 0.01; Fig. 3b and c) leading
to a significant overall increase in iron over the entire ipsilateral
hemisphere (p o 0.001; Fig. 3d). Intra-day comparisons were also
made between ipsilateral and contralateral sides, revealing a
significant increase in ROI 1 at 28 days (Fig. 3a). There was also
a significant increase in ipsilateral with respect to the contra-
lateral sides in ROI2 at days 14 and 28 day (Fig. 3b). The entire
hemisphere revealed a significant intra-day increase between
ipsilateral and contralateral sides at day 28 (Fig. 3d). However,
Fig. 1 Schematic demonstrating regions of interest selection for assess-
ment of changes in metal levels radial to the site of impact including
hippocampus as outlined. Selected ROI’s were applied to each measured
metal and extracted for statistical comparisons. Whole-hemisphere metal
concentration and equivalent ROI’s on the contralateral side were also
extracted. Nissl stained reference section (bregma-2.255 mm) used from
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no significant difference in Fe concentration was observed in
the hippocampus (Fig. 3e).
Zinc remains unchanged after brain injury
In contrast to the iron results, there were no significant
differences in Zn levels between the ipsilateral and contra-
lateral sides in ROI1, ROI2, ROI3, or the entire hemisphere
(Fig. 4a–c). Intra-day analysis in each region also revealed no
significant time point concentration differences. In the hippo-
campus, there was no significant difference between the ipsi-
lateral and contralateral sides, however, a whole brain decrease
in Zn concentration was observed between days 7 to 14 in all
ROIs (Fig. 4a–d) and hippocampus (Fig. 4e).
Copper levels are altered after brain injury
In ROI1 there was a significant increase in Cu levels between
the ipsilateral and contralateral sides across the time course
(p o 0.01) (Fig. 5a), however, this was not observed in ROI2,
ROI3, or the entire hemisphere. ROI1 intra-day comparisons
also revealed a significant increase between ipsilateral and
contralateral sides at day 14 and day 28, while ROI2 intra-day
comparison revealed a significant intra-day increase between
the ipsilateral and contralateral sides on day 14 (Fig. 5b).
No significant difference was observed in the hippocampus
between the ipsilateral and contralateral sides (Fig. 5e).
Comparison of metal changes in 3 month and 24 month-old
mice.
We compared our previously published data in three month-old
mice to our current data in 24 month-old animals as presented
in the current manuscript. A direct comparison between both
age groups revealed that Fe, Zn and Cu all increase in both the
contralateral and ipsilateral hemispheres with ageing (Fig. S1a
and b, ESI†). A comparison of ROI’s in the ipsilateral and
contralateral hemispheres between 3 and 24 month-old mice
post-TBI revealed that Fe is elevated in the uninjured contra-
lateral hemisphere in 24 month-old mice in each ROI, and that
each ROI shows a proportionally larger ipsilateral increase
in the concentration of Fe for the 24 month-old mice when
compared to the 3 month old mice from day 7 to day 28 (Fig. S2,
ESI†). Ipsilateral and contralateral regions of each ROI also
show a proportionally larger increase in concentration of Zn for
the 24 month-old mice when compared to the 3 month old
mice. In 24 month-old mice ROI1, ROI2, ROI3 and total hemi-
sphere shows a reduction in Zn in both ipsilateral and contra-
lateral hemispheres from day 7 onwards, representing a whole-
brain zinc reduction from 7–28 days’ post TBI that is not
evident in the three month-old mice (Fig. S3, ESI†). Ipsilateral
and contralateral regions of each ROI show a proportionally
larger increase in concentration of Cu for the 24 month-old
mice when compared to the 3 month old mice. In 24 month-old
mice ROI1 reveals a sustained increase in Cu concentration
from 72 hours’ post TBI. ROI2, and total hemisphere of the
24 month-old mice reveals a proportionally larger increase in
Cu in the ipsilateral hemisphere when compared to contra-
lateral hemisphere from day 7 onwards that is not evident in
the three month-old mice (Fig. S4, ESI†).
Discussion
The risk of neurodegeneration after TBI is influenced not just
by the severity of the initial insult, but also by the patient’s
age at the time of injury.44 Multiple studies of TBI confirm
a progressive rise in mortality and a decline in favourable
Fig. 2 Representative LA-ICP-MS images of both hemispheres including uninjured and time course examples from 24 hours to 28 day post-lesion.
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outcomes including dementia with each decade over 50 years of
age.11–13,16,45 As previously outlined, metals have long been
implicated in the neuropathology of aging and neurodegenera-
tive diseases. We therefore assayed Fe, Zn and Cu in the brains
of aged mice after a controlled cortical impact TBI to assess the
changes in the metallomic profile that may contribute to or
influence age-related TBI outcomes.
The regions of interest presented herein were selected to
allow the differentiation of discrete functional brain areas
surrounding the injury site that may be differentially affected
by the TBI, and to describe the extent of the metal response in
relation to the site of impact, as many studies have indicated
metal dyshomeostasis not just immediately located at the site
of injury but also in deeper tissue.20,25,46–48
We have previously shown that there is a sustained elevation
in Fe in the brains of young adult mice after TBI25 independent
of haem associated Fe caused by blood infiltration at the injury
site verified by Perls Prussian blue staining for non-haem Fe.
Moreover, it has been demonstrated with ICP-MS analysis that
cortical Fe 24 hours’ post injury is the same between ipsilateral
and contralateral regions, after an observed elevation at six
hours in the ipsilateral region, suggesting a mechanism may
exist to handle heme-associated Fe at the acute stage of
injury.49 the data presented herein shows a similar pheno-
menon in aged mice, however the magnitude of increase is
much greater in the aged mice than that exhibited in 3 month
old mice after TBI.25 Brain Fe elevation has been demonstrated
in TBI50 in conjunction with a simultaneous increase in the Fe
handling protein ferritin.51 Ferritin is a ubiquitous intracellular
protein that safely stores Fe and releases it in a controlled
fashion acting as a buffer against Fe deficiency and overload.
However, excess Fe unbound to ferritin or haem associated
proteins can initiate neurotoxicity through the formation of
reactive oxygen species (ROS) potentiating oxidative stress and
associated cell death. In AD patients Fe accumulation occurs
without an age associated increase in ferritin, increasing the
risk of oxidative stress.52 Significantly, both TBI20,25,46 and mild
TBI47,48,50 are characterised by non-haem Fe associated intra-
cellular accumulation. Moreover, Fe deposition has been
shown to be positively related to cognitive impairment in
patients with chronic mild TBI.53 Given these observations,
it is plausible that excess Fe because of TBI or mild TBI could
Fig. 3 Iron concentrations across the time course following controlled
cortical impact TBI. In ROI1 there was a significant difference in Fe levels
between the ipsilateral and contralateral sides across the time course
(####, ANOVA, p = 0.0001) (a). ROI1 intra-day comparisons also revealed
a significant difference between ipsilateral and contralateral sides at 28
days (*p o 0.05) (a). There was also a significant increase of Fe in ROI2
(###, ANOVA, p = 0.0001) (b), ROI3 (##, ANOVA, p = 0.0032) (c), and total
hemisphere (###, ANOVA p = 0.0002) (d). ROI2 intra-day analysis
revealed a significant difference between ipsilateral and contralateral sides
at days 14 (*p = 0.0380) and 28 (*p = 0.0203) (b). The entire hemisphere
revealed a significant intra-day difference between ipsilateral and contra-
lateral sides at day 28 (*p = 0.0212) (d). Hippocampus revealed no
significant overall or intra-day differences (e). Uninjured 28 day regional
analysis showed no significant changes and reflected a stable concen-
tration in all regions examined (f).
Fig. 4 Zinc concentrations across the time course following controlled
cortical impact TBI. There was no significant difference in Zn levels
between the ipsilateral and contralateral sides or intra-day in ROI1 (a),
ROI2 (b), ROI3 (c), total hemisphere (d), or hippocampus (e). Analysis of
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contribute to the onset or acceleration of neurodegenerative
conditions. Notably, excess Fe also associates with aggregation
prone proteins that initiate cell death pathways in several neuro-
degenerative diseases of aging such as AD, PD and ALS.54
Additionally, intracellular Fe accumulation has also recently
been associated with a specific cell death pathway termed
ferroptosis.55 Notably, the ferroptosis pathway is independent
from its capacity to initiate ROS production, and hence presents
another autonomous mechanism by which elevated Fe can
contribute to neurodegeneration. Our results indicate that Fe
accumulates in elevated concentrations after TBI in aged animals,
and as such may present as an influential age associated
accelerant to the now recognised increased risk of the elderly
developing dementia after TBI.
Zinc is an essential element required for efficient brain
function,56 however under injurious states Zn has been proposed
to be an influential factor in TBI pathogenesis with the litera-
ture denoting both neuroprotective and neurotoxic roles.57–61
Surprisingly then, our data revealed no change in Zn concen-
tration when comparing ipsilateral to contralateral hemispheres.
While this result is consistent with our previous study utilising
young mice,25 it should be noted that the overall level of Zn in
the brain was elevated in the aged mice, which may impact a
variety of cellular processes relevant to ageing. Zinc chelation
after TBI has been demonstrated to be protective in 6 month-old
rats62 whereby the Zn chelation induced the expression of several
neuroprotective genes in conjunction with decreased cell death
after 7 days. However, Zn chelation has also been shown to be
detrimental to outcomes post-TBI in mice (age not designated),
evidenced by a significant increase in necrotic and apoptotic
cells within 24 hours.63 Two further studies suggest that oral zinc
intake before TBI in 10 week-old rats64 and oral Zn intake post-
TBI in young adult male rats65 ameliorates the cognitive decline
observed post-TBI. These and other studies not cited herein are
confounding due to age differences, strain of animals and data
collection time points. While no difference in Zn concentration
was observed between specific ROIs in the ipsilateral and contra-
lateral hemispheres, it is possible that there is cellular trans-
location of Zn distribution, as observed by several other studies,
that leads to either neurotoxicity66 or neuroprotection.67 However,
to reveal such cellular translocation would require a more refined
delineation of analysed regions, at the sub-mm level via synchro-
tron XFM analysis or micro-particle induced X-ray emission
(m PIXE) analysis. Previous studies have shown that spatial Zn
concentrations in the mouse brain are highly compartmentalised
and heterogeneous.43,68 High levels of Zn in the hippocampus are
a significant source of biological variation,69 and this may account
for the variance we observed in our measurements. In this
experiment the scanning parameters used were optimal for
a large sample size whilst still obtaining adequate spatial
resolution to delineate brain regions at the mesoscale.70
In future experiments, we will undertake higher resolution
mapping by LA-ICPMS using a 5  5 mm pixel size to examine
changes within the injury site.
Of potential interest, however, is the observation of the
whole brain reduction of Zn concentration in the aged animals
from day 7 onwards post-TBI. Clinical studies and experimental
work with animal models have both revealed a correlation
between Zn status and neuropsychological disorders whereby
Zn deficiency has been shown to induce depression-like and
anxiety-like behaviours.71 As depression and mood disorders
are a common yet non-immediate outcome after TBI and mild
TBI, especially in the elderly,72 it would be of interest to
determine whether Zn is decreased beyond the 28 day assess-
ment period observed herein. Our results may reflect an altered
capacity of the aged brain to effectively modulate Zn under
injurious circumstances, as this effect was not observed in our
previous study utilising young mice.25
Cu in the brain is involved in mitochondrial respiration,
neurotransmitter biosynthesis, and as a cofactor for antioxidant
enzymes.73 It is a critical and essential element that also functions
in the regulation of synaptic transmission and ion channel
function. However, Cu is a transition metal that is a remarkably
potent pro-oxidant, having the ability to form hydrogen peroxide
Fig. 5 Copper concentrations across the time course following con-
trolled cortical impact TBI. In ROI1 there was a significant difference in
Cu levels between the ipsilateral and contralateral sides across the time
course (##, ANOVA, p = 0.0053), and intra-day comparisons also revealed
a significant difference between ipsilateral and contralateral sides at day 14
(*p o 0.0354) and day 28 (*p = 0.0118) (a). ROI2 intra-day comparison
revealed a significant intra-day difference between the ipsilateral and
contralateral sides on day 14 (*p = 0.0255) (b). ROI3 (c) entire hemisphere
(d), and hippocampus (e) revealed no significant overall or intra-day
differences. Analysis of uninjured tissue revealed a significant regional
copper concentration changes at 28 days in ROI1 (*p = 0.015) & ROI2
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and subsequent hydroxyl radicals at an excessive pace.74,75 Our
results revealed an overall elevation of brain Cu associated with
aging and an increased Cu concentration from day 7 to day 28
around the impact site that was not observed in our previous
study utilising younger mice.25 An elevation of Cu could potentiate
Cu toxicity in the form of oxidative stress leading to neuronal
impairment. Additionally, the collective resulting metal profile
generated by our data may be of broader relevance to the observed
heightened onset of PD after TBI45 in that elevation of Fe and Cu
in the presence of Zn depletion, has been shown in aged human
brain, with a consequence of compromised DNA integrity altering
gene expression.76 It is noteworthy that our results reveals a
similar profile of Fe, Cu and Zn, and that this profile leads to
DNA fragmentations that have been clearly demonstrated as a
component of the age related neurodegenerative disorders PD
and AD.77–80
Conclusion
This study demonstrates that a controlled cortical impact injury
results in an altered brain metal profile in aged mice. Several of
our observations are consistent with and supported by both
animal studies, and human clinical data in the literature.
However, we further reveal that there is both an age-dependent
alteration in baseline metal levels in the brain, and more impor-
tantly, there is an exaggerated alteration in metal levels seemingly
reserved for the aging brain following injury. Given that the elderly
are more likely to experience negative outcomes following a TBI,
our data may provide insight around our understanding of the
mechanisms involved in cognitive/functional decline in elderly
TBI victims.
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